What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Breast cancer
Mitch Dowsett mainly focuses on Internal medicine, Breast cancer, Oncology, Tamoxifen and Gynecology.
His study brings together the fields of Endocrinology and Internal medicine.
His Breast cancer study combines topics from a wide range of disciplines, such as Clinical trial, Estrogen and Chemotherapy.
His Oncology research is multidisciplinary, relying on both Proportional hazards model, Randomized controlled trial, Surgery, Hazard ratio and Adjuvant therapy.
The Tamoxifen study combines topics in areas such as Hormonal therapy, Adjuvant and Drug resistance.
His work carried out in the field of Gynecology brings together such families of science as Odds ratio, Guideline, Placebo, Oncotype DX and Prospective cohort study.
His most cited work include:
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (4015 citations)
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (2934 citations)
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update (1998 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Breast cancer, Oncology, Endocrinology and Tamoxifen.
His Internal medicine research focuses on Aromatase, Estrogen receptor, Anastrozole, Estrogen and Aromatase inhibitor.
As a member of one scientific family, Mitch Dowsett mostly works in the field of Breast cancer, focusing on Gynecology and, on occasion, Placebo.
The concepts of his Oncology study are interwoven with issues in Clinical trial, Chemotherapy, Randomized controlled trial, Proportional hazards model and Hazard ratio.
His study in Endocrinology focuses on Hormone, Sex hormone-binding globulin, Estrone, Testosterone and Body mass index.
His research integrates issues of Oncotype DX, Pharmacology and Endocrine system in his study of Tamoxifen.
He most often published in these fields:
- Internal medicine (86.85%)
- Breast cancer (87.80%)
- Oncology (55.31%)
What were the highlights of his more recent work (between 2016-2021)?
- Breast cancer (87.80%)
- Internal medicine (86.85%)
- Oncology (55.31%)
In recent papers he was focusing on the following fields of study:
Mitch Dowsett focuses on Breast cancer, Internal medicine, Oncology, Cancer research and Tamoxifen.
His research in Breast cancer intersects with topics in Pathology, Gene and Estrogen.
His Internal medicine study combines topics in areas such as Endocrinology and Gene expression.
His Endocrinology research is multidisciplinary, incorporating perspectives in Prospective cohort study and GREB1.
His work deals with themes such as Cancer, Chemotherapy, MEDLINE, Predictive value of tests and Oncotype DX, which intersect with Oncology.
His Cancer research research includes elements of Mutation, Transactivation, Fulvestrant, Endocrine system and ErbB.
Between 2016 and 2021, his most popular works were:
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. (424 citations)
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (362 citations)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (293 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Mitch Dowsett mostly deals with Breast cancer, Internal medicine, Oncology, Chemotherapy and Hazard ratio.
Breast cancer is a primary field of his research addressed under Cancer.
Internal medicine is closely attributed to Gene in his work.
Mitch Dowsett combines subjects such as Neoadjuvant therapy, Oestrogen receptor, Palbociclib, Estrogen receptor and Biomarker with his study of Oncology.
His study in Chemotherapy is interdisciplinary in nature, drawing from both Meta-analysis, Endocrine therapy, Disease and Discontinuation.
As part of one scientific family, Mitch Dowsett deals mainly with the area of Hazard ratio, narrowing it down to issues related to the Cohort, and often Residual risk, Primary tumor and Interquartile range.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
